A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
about
Immunotherapy: New Strategies for the Treatment of Gynecologic MalignanciesGoing viral: a review of replication-selective oncolytic adenovirusesTrial Watch:: Oncolytic viruses for cancer therapyIL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.Gene Therapy 2017: Progress and Future Directions.Oncolytic Adenovirus-Loaded Menstrual Blood Stem Cells Overcome the Blockade of Viral Activity Exerted by Ovarian Cancer AscitesOncolytic viruses: From bench to bedside with a focus on safety.Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy.Pharmacological Inhibition of β3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.Polymeric oncolytic adenovirus for cancer gene therapy.Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicineSynergistic suppression effect on tumor growth of ovarian cancer by combining cisplatin with a manganese superoxide dismutase-armed oncolytic adenovirusOncolytic adenoviruses targeted to Human Papilloma Virus-positive head and neck squamous cell carcinomas.Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesotheliomaOvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution.The evolution of adenoviral vectors through genetic and chemical surface modifications.Pharmacological modulation of anti-tumor immunity induced by oncolytic viruses.Gene therapy and imaging in preclinical and clinical oncology: recent developments in therapy and theranostics.Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma.Oncolytic viruses: a new class of immunotherapy drugs.Redirecting adenovirus tropism by genetic, chemical, and mechanical modification of the adenovirus surface for cancer gene therapy.Delivery of improved oncolytic adenoviruses by mesenchymal stromal cells for elimination of tumorigenic pancreatic cancer cells.Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.The targeted inhibitory effects of human amniotic fluid stem cells carrying CXCR4 promoter and DAL-1 on non-small cell lung carcinoma growth.[YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].Regional delivery of oncolytic vaccinia virus: it's time for clinical trials.Oncolytic adenoviruses as a therapeutic approach for osteosarcoma: A new hope.Hitting the nail on the head: combining oncolytic adenovirus-mediated virotherapy and immunomodulation for the treatment of glioma.Review: Oncolytic virotherapy, updates and future directions.Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.Designer Oncolytic Adenovirus: Coming of Age.
P2860
Q26770607-D7FB3C7A-A17C-4D57-97DD-0A56C728B0C7Q26797520-031BBDE3-0704-4B17-A9CD-011453316305Q27021951-8D2FD92C-A372-407E-A7CA-3CD314AC4AF0Q30355682-429C82FF-FF8B-4D0E-8D41-BC1BDBBBF92EQ33891559-4153179C-4B01-477D-8CFD-B86BA4E30823Q33904378-AB0CF0A9-6626-40D7-B7E2-23DA1A23F5AEQ34044071-C92305B6-3073-44C4-B72E-4E517C85027CQ35087653-2CF5E086-10FF-4C27-A8CA-1E50B37790BCQ35226511-93EABC4E-7D9B-4B1A-8F6C-EA7D3D142C74Q35620238-AFE94229-52F7-4DA1-9821-2595533DB5A8Q35864258-9747EEAE-80E8-42DE-A093-BB716D6DF626Q36344901-4862EF39-0746-4850-9DD0-6509263C0D70Q36757131-9135B497-1B2E-4BBA-A2C8-D03DF4BE26E3Q37045403-D3E25F7B-EF8F-4E95-8F0C-8785C333CE3CQ37224420-38CC261C-F1D0-41F8-9C22-3E0CB44BA93AQ37358145-C25DA38C-C476-48FE-B797-30901B8A8B98Q37385240-DE303992-B27F-4877-94D3-900BC5DA32D3Q37611680-F8A590DC-A176-4C01-810A-DC554A6EABAFQ37718560-D9400A75-465C-4056-8C5A-2D3945144333Q38189250-C0EE3B6F-FA10-4E78-9CB3-FA9BFCE74321Q38237657-308CDF8F-2CCE-4188-A3A9-4CE7F85671CDQ38297124-52F0C9E7-1CB3-49E4-AFF4-17E7C5102F68Q38534285-827A31B6-A828-4743-A171-371896C751FCQ38577450-A8A91C52-3301-4D28-845C-638079E8E46BQ38769919-4FEA47A7-7860-4721-9BFE-FA39838A8B73Q38914555-9BF47DCB-2A40-4109-8904-3DA39E2E0F69Q38949072-F6E4EFB0-1655-4152-89D1-50666D873EDBQ41048929-4793E22C-7AD1-400E-9C43-72D1136D773EQ41133867-D3DB981C-10C3-4E9E-BA83-61243EEC8F31Q42560832-D71451DB-7B1E-46DF-9305-44212E480C53Q47095296-632FE6D5-B17B-4C93-BE96-AB55B05FC2DBQ47141309-F91A8492-429A-4A11-AAC5-3753AE175BA2Q47160989-B0070CD5-E8E8-453B-81ED-8A9C51B8CE2CQ54965295-903BCC8A-0470-4447-AEBA-4EA43513E474Q55467684-C9B59EF3-E3C7-4492-8744-FC37DE11124E
P2860
A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A phase I clinical trial of Ad ...... with recurrent ovarian cancer
@en
A phase I clinical trial of Ad ...... with recurrent ovarian cancer.
@nl
type
label
A phase I clinical trial of Ad ...... with recurrent ovarian cancer
@en
A phase I clinical trial of Ad ...... with recurrent ovarian cancer.
@nl
prefLabel
A phase I clinical trial of Ad ...... with recurrent ovarian cancer
@en
A phase I clinical trial of Ad ...... with recurrent ovarian cancer.
@nl
P2093
P2860
P921
P1433
P1476
A phase I clinical trial of Ad ...... with recurrent ovarian cancer
@en
P2093
Elena A Kashentseva
Igor P Dmitriev
Karan P Singh
Kenneth H Kim
Raymond D Harris
Ronald D Alvarez
Rosemarie Aurigemma
Sejong Bae
Souheil Saddekni
P2860
P304
P356
10.1016/J.YGYNO.2013.06.003
P407
P577
2013-06-10T00:00:00Z